149 related articles for article (PubMed ID: 9541188)
1. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat.
Sinha S; Kaseta J; Santner SJ; Demers LM; Bremmer WJ; Santen RJ
Breast Cancer Res Treat; 1998 Mar; 48(1):45-51. PubMed ID: 9541188
[TBL] [Abstract][Full Text] [Related]
2. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
3. The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511.
Kudoh M; Susaki Y; Ideyama Y; Nanya T; Okada M; Shikama H; Fujikura T
J Steroid Biochem Mol Biol; 1995 Sep; 54(5-6):265-71. PubMed ID: 7577709
[TBL] [Abstract][Full Text] [Related]
4. The role of estrogen in the feedback regulation of follicle-stimulating hormone secretion in the female rat.
Bhatnagar AS; Batzl C; Häusler A; Nogués V
J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):161-6. PubMed ID: 8274431
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.
Schieweck K; Bhatnagar AS; Batzl C; Lang M
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):633-6. PubMed ID: 8476774
[TBL] [Abstract][Full Text] [Related]
6. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
Bhatnagar AS; Häusler A; Schieweck K; Lang M; Bowman R
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1021-7. PubMed ID: 2149502
[TBL] [Abstract][Full Text] [Related]
7. Rainbow trout, Oncorhynchus mykiss, as a model for aromatase inhibition.
Shilling AD; Carlson DB; Williams DE
J Steroid Biochem Mol Biol; 1999; 70(1-3):89-95. PubMed ID: 10529006
[TBL] [Abstract][Full Text] [Related]
8. [The role of the ovarian steroid aromatase in pathogenesis of reproductive cycles disorders].
Tarasenko LV; Reznikov OH
Fiziol Zh (1994); 2007; 53(1):11-5. PubMed ID: 17500197
[TBL] [Abstract][Full Text] [Related]
9. Extraovarian gonadotropin negative feedback revealed by aromatase inhibition in female marmoset monkeys.
Kraynak M; Flowers MT; Shapiro RA; Kapoor A; Levine JE; Abbott DH
Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E507-E514. PubMed ID: 28679622
[TBL] [Abstract][Full Text] [Related]
10. Effects of letrozole on hippocampal and cortical catecholaminergic neurotransmitter levels, neural cell adhesion molecule expression and spatial learning and memory in female rats.
Aydin M; Yilmaz B; Alcin E; Nedzvetsky VS; Sahin Z; Tuzcu M
Neuroscience; 2008 Jan; 151(1):186-94. PubMed ID: 18061360
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E.
Wickman S; Dunkel L
J Clin Endocrinol Metab; 2001 Oct; 86(10):4887-94. PubMed ID: 11600558
[TBL] [Abstract][Full Text] [Related]
12. Developmental regulation of baboon fetal ovarian maturation by estrogen.
Zachos NC; Billiar RB; Albrecht ED; Pepe GJ
Biol Reprod; 2002 Oct; 67(4):1148-56. PubMed ID: 12297530
[TBL] [Abstract][Full Text] [Related]
13. Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
Tekmal RR; Kirma N; Gill K; Fowler K
Endocr Relat Cancer; 1999 Jun; 6(2):307-14. PubMed ID: 10731124
[TBL] [Abstract][Full Text] [Related]
14. [Aromatase inhibitors: pharmacological aspects].
de Crémoux P
Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
[TBL] [Abstract][Full Text] [Related]
15. The pharmacology of letrozole.
Haynes BP; Dowsett M; Miller WR; Dixon JM; Bhatnagar AS
J Steroid Biochem Mol Biol; 2003 Oct; 87(1):35-45. PubMed ID: 14630089
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors and their application in breast cancer treatment*.
Brodie AM; Njar VC
Steroids; 2000 Apr; 65(4):171-9. PubMed ID: 10713305
[TBL] [Abstract][Full Text] [Related]
17. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Lamb HM; Adkins JC
Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of MEN 11066, a novel potent and selective aromatase inhibitor.
Muratori M; Lippi A; Mancina R; Iafrate EM; Cirillo R; Lopez G; Bigioni M; Maggi M; Criscuoli M; Maggi CA
J Steroid Biochem Mol Biol; 2003 Apr; 84(5):503-12. PubMed ID: 12767275
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
20. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
